Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.49 |
| ▸ | RARB | P10826 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.47 |
| ▸ | RXRA | P19793 | 1/20 | 0.47 |
| ▸ | RXRB | P28702 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18494086 | 0.88 | SMN1; SMN2 (0.54) | SMN1; SMN2RARBHDAC1HDAC2KMT2A | |
| SCHEMBL17169733 | 0.87 | SMN1; SMN2 (0.53) | SMN1; SMN2RARBHDAC1HDAC2KMT2A | |
| SCHEMBL18494088 | 0.85 | SMN1; SMN2 (0.50) | SMN1; SMN2RARBHDAC1HDAC2KMT2A | |
| SCHEMBL24897600 | 0.83 | L3MBTL1 (0.60) | RARBHDAC1HDAC2KMT2ANPC1 | |
| SCHEMBL20805332 | 0.82 | SMN1; SMN2 (0.48) | SMN1; SMN2MCL1RARBHDAC1HDAC2 | |
| SCHEMBL2116281 | 0.82 | ALOX15 (0.54) | SMN1; SMN2RARBHDAC1HDAC2KMT2A | |
| SCHEMBL10018592 | 0.81 | SMN1; SMN2 (0.61) | SMN1; SMN2MCL1KMT2AHRH3MEN1 | |
| SCHEMBL1283871 | 0.81 | SMN1; SMN2 (1.00) | SMN1; SMN2EPHX2NR1H4MCL1KMT2A | |
| SCHEMBL22144522 | 0.81 | RARB (0.54) | SMN1; SMN2RARBHDAC1HDAC2KMT2A | |
| SCHEMBL22932078 | 0.79 | ALDH1A1 (0.50) | RARBHDAC1HDAC2KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018156-A1 | SPIROCYCLIC COMPOUNDS | C4 THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-11623929-B2 | Spirocyclic compounds | C4 THERAPEUTICS, INC. (US) | 2023-04-11 | — | — | US | disclosed |
| US-11584748-B2 | Spirocyclic compounds | C4 THERAPEUTICS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20230019060-A1 | HETEROCYCLIC COMPOUNDS FOR MEDICAL TREATMENT | C4 THERAPEUTICS, INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-11524949-B2 | Degraders and Degrons for targeted protein degradation | C4 THERAPEUTICS, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| US-20210070763-A1 | SPIROCYCLIC COMPOUNDS | C4 THERAPEUTICS, INC. (US) | 2021-03-11 | — | — | US | disclosed |
| US-20210032245-A1 | SPIROCYCLIC COMPOUNDS | C4 THERAPEUTICS, INC. (US) | 2021-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230019060-A1 | HETEROCYCLIC COMPOUNDS FOR MEDICAL TREATMENT | CRBN, MDM2, RBX1 | SMN1; SMN2 1800/4885EPHX2 2893/4885NR1H4 1941/4885 |
| US-20210070763-A1 | SPIROCYCLIC COMPOUNDS | CRBN, XIAP, RBX1 | SMN1; SMN2 2504/4885EPHX2 2891/4885NR1H4 1588/4885 |
| US-20240018156-A1 | SPIROCYCLIC COMPOUNDS | CRBN, XIAP, RBX1 | SMN1; SMN2 2504/4885EPHX2 2891/4885NR1H4 1588/4885 |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | STUB1, MDM2, USP30 | SMN1; SMN2 1270/4885EPHX2 4104/4885NR1H4 3297/4885 |
| US-11623929-B2 | Spirocyclic compounds | CRBN, XIAP, RBX1 | SMN1; SMN2 2504/4885EPHX2 2891/4885NR1H4 1588/4885 |
| US-20210032245-A1 | SPIROCYCLIC COMPOUNDS | CRBN, RBX1, XIAP | SMN1; SMN2 2170/4885EPHX2 3306/4885NR1H4 1938/4885 |
| US-11524949-B2 | Degraders and Degrons for targeted protein degradation | STUB1, MDM2, USP30 | SMN1; SMN2 1270/4885EPHX2 4104/4885NR1H4 3297/4885 |
| US-11584748-B2 | Spirocyclic compounds | CRBN, RBX1, XIAP | SMN1; SMN2 2170/4885EPHX2 3306/4885NR1H4 1938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.